Isaac Barchas Sells 15,248 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 15,248 shares of Immunome stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $26.06, for a total value of $397,362.88. Following the sale, the director directly owned 72,416 shares in the company, valued at $1,887,160.96. The trade was a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total value of $543,090.40.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The stock was sold at an average price of $24.20, for a total value of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The shares were sold at an average price of $24.11, for a total value of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total value of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The shares were sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Stock Up 2.6%

Immunome stock traded up $0.66 during mid-day trading on Monday, hitting $25.69. 1,228,372 shares of the company were exchanged, compared to its average volume of 1,385,460. The business has a fifty day moving average of $21.49 and a 200 day moving average of $22.16. Immunome, Inc. has a 1-year low of $8.66 and a 1-year high of $27.65. The company has a market capitalization of $2.91 billion, a PE ratio of -10.79 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.12. Research analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current year.

Hedge Funds Weigh In On Immunome

A number of institutional investors have recently modified their holdings of IMNM. BlackRock Inc. acquired a new position in shares of Immunome during the second quarter worth approximately $186,588,000. T. Rowe Price Investment Management Inc. grew its stake in shares of Immunome by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after purchasing an additional 5,003,824 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Immunome by 8,659.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after purchasing an additional 2,823,144 shares in the last quarter. Primecap Management Co. CA increased its holdings in shares of Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after purchasing an additional 1,667,432 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in Immunome in the 4th quarter worth approximately $30,710,000. 44.58% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

IMNM has been the topic of a number of recent analyst reports. Wedbush restated an “outperform” rating and issued a $31.00 price target on shares of Immunome in a research report on Tuesday, July 21st. Barclays initiated coverage on shares of Immunome in a report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price objective for the company. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Leerink Partners cut their price objective on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Finally, Truist Financial increased their target price on Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $34.18.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.